An Open-Label, Single-Center, Single-Dose, Phase I Study to Assess the Mass Balance of [14C] SY-5007 in Healthy Male Subjects in China
Latest Information Update: 10 Apr 2024
At a glance
- Drugs SY-5007 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Shouyao Holdings
Most Recent Events
- 10 Apr 2024 New trial record